• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems?

    Simply Wall St·07/08/2026 09:29:48
    Listen to the news
    • DexCom, Inc. previously initiated a voluntary Class II recall of specific Dexcom G7 continuous glucose monitoring sensor lots that had been stolen during the destruction process, including devices with improper sterilization and potential sensor inaccuracies that could lead to infections or incorrect glucose readings across multiple countries.
    • The incident highlights vulnerabilities in DexCom’s supply chain controls and data monitoring, as the company is relying on app usage data rather than distribution records to track affected sensors.
    • We’ll now examine how this recall, particularly the quality and safety risks tied to improperly sterilized and inaccurate sensors, influences DexCom’s investment narrative.

    Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

    DexCom Investment Narrative Recap

    To own DexCom, you need to believe continuous glucose monitoring will stay central to diabetes care and that DexCom can convert broader coverage into active users. The recent Class II G7 sensor recall raises fresh questions about quality controls and supply chain oversight, but based on what is known so far, it does not clearly change the key near term catalysts or the primary risk around potential CMS pricing pressure.

    The most relevant recent announcement here is the series of FDA enforcement Class II recalls of Dexcom iOS and WatchOS apps for processing delays that could affect glucose alerts. Taken together with the G7 sensor recall, these software and hardware issues put more focus on DexCom’s ability to manage product reliability at scale, which sits alongside reimbursement decisions and CGM adoption as critical moving parts for the story.

    Yet against the growth potential, investors also need to watch how recurring recalls could compound DexCom’s existing supply chain and cost risks…

    Read the full narrative on DexCom (it's free!)

    DexCom's narrative projects $6.7 billion revenue and $1.4 billion earnings by 2029.

    Uncover how DexCom's forecasts yield a $83.42 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    DXCM 1-Year Stock Price Chart
    DXCM 1-Year Stock Price Chart

    Some of the lowest analysts were already assuming only about 10 percent annual revenue growth and US$1.2 billion in earnings by 2029, so this recall could further test that cautious view and your own expectations.

    Explore 6 other fair value estimates on DexCom - why the stock might be worth as much as 69% more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

    Want Some Alternatives?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.